Precigen announced the appointment of Phil Tennant as the Company’s chief commercial officer. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 AdenoVerse gene therapy in recurrent respiratory papillomatosis. Tennant will report to Precigen’s President and CEO, Helen Sabzevari, PhD, and will join Precigen’s executive leadership team.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGEN:
- Biotech Alert: Searches spiking for these stocks today
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Precigen’s Annual Meeting Decisions and Director Departure
- Precigen price target raised to $10 from $7 at Stifel
- Precigen says Phase 1/2 PRGN-2012 study met primary endpoints
Questions or Comments about the article? Write to editor@tipranks.com